Becton, Dickinson and Company $BDX Shares Bought by Atria Investments Inc

Atria Investments Inc lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,529 shares of the medical instruments supplier’s stock after acquiring an additional 3,975 shares during the period. Atria Investments Inc’s holdings in Becton, Dickinson and Company were worth $5,153,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Gilbert & Cook Inc. grew its stake in shares of Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 56 shares during the period. Mendel Money Management grew its position in Becton, Dickinson and Company by 2.6% during the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after acquiring an additional 58 shares during the period. Focus Financial Network Inc. increased its stake in Becton, Dickinson and Company by 2.2% during the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after acquiring an additional 58 shares during the last quarter. CX Institutional raised its holdings in shares of Becton, Dickinson and Company by 3.6% in the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 60 shares during the period. Finally, Private Trust Co. NA lifted its stake in shares of Becton, Dickinson and Company by 1.6% in the 2nd quarter. Private Trust Co. NA now owns 3,927 shares of the medical instruments supplier’s stock valued at $676,000 after purchasing an additional 61 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Down 1.0%

Shares of NYSE BDX opened at $175.95 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $185.02. The stock’s 50-day simple moving average is $198.82 and its 200-day simple moving average is $192.26. The firm has a market cap of $50.10 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 2.30 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the prior year, the business posted $3.43 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its board has initiated a stock buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of research firms recently issued reports on BDX. Wells Fargo & Company dropped their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. JPMorgan Chase & Co. dropped their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Barclays initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price on the stock. Royal Bank Of Canada set a $172.00 price target on Becton, Dickinson and Company in a report on Tuesday. Finally, Piper Sandler reissued a “neutral” rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $195.46.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 2,463 shares of company stock valued at $501,530. 0.40% of the stock is currently owned by insiders.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Citi raised its price target after a life‑sciences sale update, signaling potential value support if BDx proceeds with portfolio moves. Citi raises Becton Dickinson PT to $198
• Positive Sentiment: Jefferies issued a buy, supporting the view that BDx’s portfolio reshaping and product investments can sustain growth. Becton Dickinson Gets a Buy from Jefferies
• Positive Sentiment: TD Cowen nudged its target higher to $189 (hold), reflecting modest upside from current levels and adding another analyst vote of confidence. TD Cowen adjusts Becton Dickinson PT to $189
• Neutral Sentiment: Company Q4 review: management says portfolio reshaping and product investments offset tariff headwinds — useful context for earnings quality but not an immediate directional catalyst. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Negative Sentiment: Zacks Research cut BDX from “hold” to “strong sell,” a notable downgrade that likely pressured sentiment and contributed to the share weakness. Zacks Research downgrade
• Negative Sentiment: AmericanBankingNews reports Citigroup lowered a prior target (headline shows a cut to $232), adding further mixed signals from the sell‑side. Citigroup Lowers Becton Dickinson PT to $232
• Negative Sentiment: JPMorgan and Wells Fargo issued pessimistic forecasts in separate notes, increasing analyst pressure and downside risk in the near term. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
• Negative Sentiment: Coverage flow drove a gap‑down headline after the analyst activity, reflecting short‑term selling pressure from downgrades and mixed guidance expectations. Shares gap down on analyst downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.